Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Hao Tseng

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
The American Journal of Gastroenterology|July 31, 2024
Response to Li et alCheng-Hao Tseng, Han-Mo Chiu
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 24, 2019
Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be DoneYao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Hepatology International|August 15, 2020
Is tenofovir more effective than entecavir to prevent hepatocellular carcinoma? The controversy goes onCheng-Hao Tseng, Mindie H Nguyen, Yao-Chun Hsu
The Lancet. Gastroenterology & Hepatology|January 14, 2021
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' replyCheng-Hao Tseng, Yao-Chun Hsu, Mindie H Nguyen
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 22, 2021
ReplyYao-Chun Hsu, Cheng-Hao Tseng, Mindie H Nguyen
Clinical and Molecular Hepatology|March 14, 2023
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harmYao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Seminars in Liver Disease|June 23, 2021
Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future PerspectiveYao-Chun Hsu, Cheng-Hao Tseng, Yen-Tsung Huang, et al.
Gut|February 24, 2010
A 61-year-old man with abdominal pain for 6 monthsCheng-Hao Tseng, Jyh-Ming Liou, Kao-Lang Liu, et al.
Digestive Diseases (Basel, Switzerland)|September 15, 2020
Increasing Age and Nonliver Comorbidities in Patients with Chronic Hepatitis B in Taiwan: A Nationwide Population-Based AnalysisCheng-Hao Tseng, Yao-Chun Hsu, Hsiu J Ho, et al.
Gut|October 21, 2021
Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunitiesYao-Chun Hsu, Cheng-Hao Tseng, Tung-Hung Su, et al.
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
The American Journal of Gastroenterology|July 31, 2024
Response to Li et alCheng-Hao Tseng, Han-Mo Chiu
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 24, 2019
Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be DoneYao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Hepatology International|August 15, 2020
Is tenofovir more effective than entecavir to prevent hepatocellular carcinoma? The controversy goes onCheng-Hao Tseng, Mindie H Nguyen, Yao-Chun Hsu
The Lancet. Gastroenterology & Hepatology|January 14, 2021
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' replyCheng-Hao Tseng, Yao-Chun Hsu, Mindie H Nguyen
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 22, 2021
ReplyYao-Chun Hsu, Cheng-Hao Tseng, Mindie H Nguyen
Clinical and Molecular Hepatology|March 14, 2023
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harmYao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Seminars in Liver Disease|June 23, 2021
Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future PerspectiveYao-Chun Hsu, Cheng-Hao Tseng, Yen-Tsung Huang, et al.
Gut|February 24, 2010
A 61-year-old man with abdominal pain for 6 monthsCheng-Hao Tseng, Jyh-Ming Liou, Kao-Lang Liu, et al.
Digestive Diseases (Basel, Switzerland)|September 15, 2020
Increasing Age and Nonliver Comorbidities in Patients with Chronic Hepatitis B in Taiwan: A Nationwide Population-Based AnalysisCheng-Hao Tseng, Yao-Chun Hsu, Hsiu J Ho, et al.
Gut|October 21, 2021
Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunitiesYao-Chun Hsu, Cheng-Hao Tseng, Tung-Hung Su, et al.
Pageof 10